Browse > Article
http://dx.doi.org/10.3857/roj.2017.00262

Extraordinary radiation super-sensitivity accompanying with sorafenib combination therapy: what lies beneath?  

Lee, Jayoung (Department of Radiation Oncology, Pusan National University Yangsan Hospital)
Lee, Ju Hye (Department of Radiation Oncology, Pusan National University Yangsan Hospital)
Yoon, Hanbin (Department of Radiation Oncology, Pusan National University Yangsan Hospital)
Lee, Ho Jeong (Department of Radiation Oncology, Pusan National University Yangsan Hospital)
Jeon, Hosang (Department of Radiation Oncology, Pusan National University Yangsan Hospital)
Nam, Jiho (Department of Radiation Oncology, Pusan National University Yangsan Hospital)
Publication Information
Radiation Oncology Journal / v.35, no.2, 2017 , pp. 185-188 More about this Journal
Abstract
Primary liver tumor, especially hepatocellular carcinoma (HCC), is a common cause of cancer death worldwide. The incidence is generally higher in Asian countries than in western countries. Carcinogenesis of HCC is often associated with hepatitis viral infections. Current standard treatment of HCC is surgical resection or transplantation in patients with early stage disease. However, the patient with advanced stage disease, surgical resection is often limited. Sorafenib or other treatment modalities are not so effective as well. We report a case of unusual radiation super-sensitivity in advanced stage HCC, and review the literature.
Keywords
Hepatocellular carcinoma; Radiotherapy; Sorafenib;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013;47 Suppl:S2-6.   DOI
2 Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol 2014;20:4115-27.   DOI
3 Ohri N, Dawson LA, Krishnan S, et al. Radiotherapy for hepatocellular carcinoma: new indications and directions for future study. J Natl Cancer Inst 2016;108;djw133.   DOI
4 McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011;15:223-43, vii-x.
5 Brade AM, Ng S, Brierley J, et al. Phase 1 Trial of sorafenib and stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2016;94:580-7.   DOI
6 Chen SW, Lin LC, Kuo YC, Liang JA, Kuo CC, Chiou JF. Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2014;88:1041-7.   DOI